A PLACEBO CONTROLLED, DOUBLE-BLIND STUDY OF CHEMICALLY MODIFIED TETRACYCLINE

化学修饰四环素的安慰剂对照、双盲研究

• 批准号: 7375358
• 负责人: MARIA E RYAN
• 金额: $ 5.05万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375358
• 关键词: PLACEBO; CONTROLLED; DOUBLE; BLIND; STUDY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is to determine if a newly developed experimental drug (COL-3) can reduce the levels of tissue destructive enzymes and bone breakdown products in the tiny amount of fluid that leaks out of the tissue around the teeth. Periodontal (gum) disease causes inflammation (reddening and bleeding) of the gums and can result in tooth loss. COL-3 is an experimental new drug derived from a commonly used drug called "tetracycline"which has been used in the treatment of periodontal (gum) disease.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项研究是为了确定一种新开发的实验性药物（COL-3）是否可以降低从牙齿周围组织泄漏出来的微量液体中的组织破坏酶和骨分解产物的水平。牙周炎（牙龈）疾病会导致牙龈发炎（发红和出血），并可能导致牙齿脱落。COL-3是一种实验性新药，来源于一种被称为“四环素“的常用药物，该药物已用于治疗牙周（牙龈）疾病。